Download 10% 90% 41%

Value of Medical Innovation in
Mantle Cell Lymphoma
The incidence of cancer continues to increase worldwide. In recent years,
substantial progress has been made through medical innovation to help people
manage diseases such as cancer, allowing them to live longer.1 Much work remains
to be done, however, particularly for rare diseases that have not historically been
a focus of medical innovations.
MCL
Mantle cell lymphoma (MCL) is a sub-type of lymphoma—a cancer of white
blood cells called lymphocytes, which normally help the body fight infection.
Lymphomas, which usually begin in the lymph nodes, are divided in two
categories: Hodgkin lymphoma and non-Hodgkin lymphoma (NHL), which is
further divided into several sub-types, including MCL.2
NHL
lymphoma
Incidence of NHL has increased:1
90
%
1975
MCL
10%
%
49.9%
as of 1990
1990
1992
1994
1998
2000
Despite advances
in the treatment of
NHL as a whole,
the survival rate for
patients with MCL
remains considerably
lower.
as of 2005
54.6%
as of 2009
2004
2006
2008
2005
Pre-1995
Chemotherapy is the
standard treatment for NHL
1995
Autologous bone marrow
transplantation improves
survival for patients with
diffuse large B-cell lymphoma4
½
2002
of NHLs3
70.6%
41
MCL
year
year
1
rate survival rate 1
survival
less than
accounts
for
2010
5 5
NHL
Hodgkin
1997
Proteasome
inhibitor
approved by
FDA4
2002
Radioimmunotherapy
approved by FDA4
2010
2008
Antifolate
approved by
the FDA4
First targeted therapy
approved by FDA4
Roughly
of people
diagnosed with
MCL are over
the age of 68
about
4,000
new cases of MCL are diagnosed in
the United States each year2
Men are more than
60%
more likely to be affected by
NHL than woman2
Caucasians are over
55%
509,065
people living with NHL5
69,740
expected new cases of NHL in 20135
more likely to be
affected by NHL than
African Americans2
1.
National Cancer Institute. Surveillance Epidemiology and End Results (SEER). April 2012. Available at http://seer.cancer.gov. Accessed May 2013.
2.
Leukemia and Lymphoma Society. Mantle Cell Lymphoma Facts. July 2012.
3.
Li ZM, Zucca E, Ghielmini M. Open questions in the management of mantle cell lymphoma. Cancer Treat Rev. 2013. doi: 10.1016/j.ctrv.2012.12.013.
4.
American Society of Clinical Oncology. Progress Against Lymphoma. May 2013.
5.
National Cancer Institute. SEER Stat Fact Sheets: Non-Hodgkin Lymphoma. May 2013. Available at http://seer.cancer.gov/statfacts/html/nhl.html.
6.
Shah BD, Martin P, Sotomayor EM. Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches. Cancer Control. 2012;19:227-235.